Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: A randomised, double-blind placebo-controlled trial

The Lancet Respiratory Medicine

Volumn 3, Issue 2, 2015, Pages 131-138

  Lerman, Caryn ^a   Schnoll, Robert A ^b   Hawk, Larry W ^c   Cinciripini, Paul ^d   George, Tony P ^e   Wileyto, E Paul ^f   Swan, Gary E ^g   Benowitz, Neal L ^h   Heitjan, Daniel F ^f   Tyndale, Rachel F ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g STANFORD UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYCOTININE; BIOLOGICAL MARKER; CYTOCHROME P450 2A6; ESTROGEN; NICOTINE PATCH; PLACEBO; VARENICLINE; COTININE; HYDROXYCOTININE; NICOTINE; NICOTINE GUM; NICOTINIC AGENT;

ABNORMAL DREAMING; ADULT; ANXIETY; ANXIETY DISORDER; ARTICLE; ATTENTION DISTURBANCE; COGNITIVE THERAPY; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; EDUCATION; EMPLOYMENT STATUS; ETHNICITY; FEMALE; FOLLOW UP; HELP SEEKING BEHAVIOR; HOSPITALIZATION; HUMAN; INCOME; INTENTION TO TREAT ANALYSIS; INTERVENTION STUDY; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PILL; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SEX DIFFERENCE; SIDE EFFECT; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT DURATION; WITHDRAWAL SYNDROME; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

ADULT; BIOMARKERS; COTININE; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME; VARENICLINE;

EID: 84925692950     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70294-2     Document Type: Article

References (36)

1. Quitting smoking among adults-United States, 2001-2010. MMWR Morb Mortal Wkly Rep 2011, 60:1513-1591. CDC.
2. World Health Organization tobacco fact sheet (no. 339) 2013, WHO, World Health Organization Media Centre, Geneva, Switzerland.
3. Eriksen M, Mackay J, Ross H. The tobacco atlas, 4th edn. Atlanta, GA: American Cancer Society; New York, NY: World Lung Foundation.
4. West R, DiMarino ME, Gitchell J, McNeill A Impact of UK policy initiatives on use of medicines to aid smoking cessation. Tob Control 2005, 14:166-171.
5. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline 2008, US Department of Health and Human Services. Public Health Service, Rockville, MD.
6. Hughes JR, Stead LF, Lancaster T Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007, 1. CD000031.
7. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008, 63:717-724.
8. Kralikova E, Kmetova A, Stepankova L, Zvolska K, Davis R, West R Fifty-two-week continuous abstinence rates of smokers being treated with varenicline versus nicotine replacement therapy. Addiction 2013, 108:1497-1502.
9. Wang C, Cho B, Xiao D, Wajsbrot D, Park PW Effectiveness and safety of varenicline as an aid to smoking cessation: results of an inter-Asian observational study in real-world clinical practice. Int J Clin Pract 2013, 67:469-476.
10. Bough KJ, Lerman C, Rose JE, et al. Biomarkers for smoking cessation. Clin Pharmacol Ther 2013, 93:526-538.
11. Dempsey D, Tutka P, Jacob P, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 2004, 76:64-72.
12. Ho M, Mwenifumbo J, Al Koudsi N, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther 2009, 85:635-643.
13. Lerman C, Tyndale R, Patterson F, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 2006, 79:600-608.
14. Patterson F, Schnoll RA, Wileyto EP, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 2008, 84:320-325.
15. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav 2009, 92:6-11.
16. Cahill K, Stevens S, Perera R, Lancaster T Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013, 5. CD009329.
17. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55.
18. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991, 86:1119-1127.
19. St Helen G, Novalen M, Heitjan DF, et al. Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev 2012, 21:1105-1114.
20. Hughes JR, Hatsukami DK, Pickens RW, Krahn D, Malin S, Luknic A Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology (Berl) 1984, 83:82-87.
21. Schnoll RA, Patterson F, Wileyto EP, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med 2010, 152:144-151.
22. Brown R, Burgess E, Sales S, Whiteley J Reliability and validity of a smoking timeline follow-back interview. Psychol Addict Behav 1988, 12:101-112.
23. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 2003, 5:13-25.
24. Norton EC, Wang H, Ai C Computing interaction effects and standard errors in logit and probit models. Stata J 2004, 4:154-167.
25. DeLong ER, DeLong DM, Clarke-Pearson DL Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
26. Lachin JM A review of methods for futility stopping based on conditional power. Stat Med 2005, 24:2747-2764.
27. Chenoweth MJ, Novalen M, Hawk LW, et al. Known and novel sources of variability in nicotine metabolite ratio in a large sample of treatment-seeking smokers. Cancer Epidemiol Biomarkers Prev 2014, 23:1773-1782.
28. Cook RJ, Sackett DL The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995, 310:452-454.
29. Liberman JN, Lichtenfeld MJ, Galaznik A, et al. Adherence to varenicline and associated smoking cessation in a community-based patient setting. J Manag Care Pharm 2013, 19:125-131.
30. Lerman C, Jepson C, Wileyto EP, et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin Pharmacol Ther 2010, 87:553-557.
31. Rao Y, Hoffmann E, Zia M, et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 2000, 58:747-755.
32. Tang DW, Hello B, Mroziewicz M, Fellows LK, Tyndale RF, Dagher A Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI. Neuroimage 2012, 60:2136-2143.
33. Sofuoglu M, Herman AI, Nadim H, Jatlow P Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine. Neuropsychopharmacology 2012, 37:1509-1516.
34. Kalousova L, Burgard SA Unemployment, measured and perceived decline of economic resources: Contrasting three measures of recessionary hardships and their implications for adopting negative health behaviors. Soc Sci Med 2014, 106:28-34.
35. Kotz D, Brown J, West R Prospective cohort study of the effectiveness of smoking cessation treatments used in the "real world". Mayo Clin Proc 2014, 89:1360-1367.
36. Lea RA, Dickson S, Benowitz NL Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. J Anal Toxicol 2006, 30:386-389.